Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 17,103 shares at $132.58 ($2.3M) on 2018-05-14, disclosed to the SEC on 2018-05-16.
Open-market sale of $2.3M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.58 | 100 | $13K | 0.6% |
| 2 | $136.22 | 1,525 | $208K | 8.9% |
| 3 | $136.22 | 1,525 | $208K | 8.9% |
| 4 | $137.28 | 1,558 | $214K | 9.1% |
| 5 | $137.28 | 1,558 | $214K | 9.1% |
| 6 | $137.83 | 167 |
| $23K |
| 1.0% |
| 7 | $137.83 | 167 | $23K | 1.0% |
| 8 | $139.00 | 100 | $14K | 0.6% |
| 9 | $139.00 | 100 | $14K | 0.6% |
| 10 | $133.11 | 700 | $93K | 4.0% |
| 11 | $133.11 | 700 | $93K | 4.0% |
| 12 | $134.41 | 300 | $40K | 1.7% |
| 13 | $134.41 | 300 | $40K | 1.7% |
| 14 | $135.83 | 1,000 | $136K | 5.8% |
| 15 | $136.72 | 400 | $55K | 2.3% |
| 16 | $138.35 | 3,297 | $456K | 19.5% |
| 17 | $138.89 | 1,803 | $250K | 10.7% |
| 18 | $138.89 | 1,803 | $250K | 10.7% |
| Total | $137.10 avg | 17,103 | $2.3M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $2.9M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |